RESUMEN
PURPOSE OF REVIEW: We describe the impact of COVID-19 on PEPFAR programs in Africa and how PEPFAR adapted and leveraged its interventions to the changing landscape of the COVID-19 pandemic. RECENT FINDINGS: To mitigate the potential impact of COVID-19 on the HIV response and protect the gains, continuity of treatment was the guiding principle regarding the provision of services in PEPFAR-supported countries. As the COVID-19 pandemic matured, PEPFAR's approach evolved from a strictly "protect and salvage" approach to a "restore and accelerate" approach that embraced innovative adaptations in service and "person-centered" care. The impact of service delivery interruptions caused by COVID-19 on progress towards HIV epidemic control in PEPFAR-supported African countries remains undetermined. With COVID vaccine coverage many months away and more transmissible variants being reported, Africa may experience more pandemic surges. HIV programs will depend on nimble and innovative adaptations in prevention and treatment services in order to advance epidemic control objectives.
Asunto(s)
COVID-19 , Infecciones por VIH , África/epidemiología , COVID-19/epidemiología , COVID-19/prevención & control , Vacunas contra la COVID-19 , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/epidemiología , Infecciones por VIH/prevención & control , Humanos , Cooperación Internacional , Pandemias/prevención & control , SARS-CoV-2RESUMEN
Andersen's Behavioral Model (ABM) provides a framework for understanding how patient and environmental factors impact health behaviors and outcomes. We compared patient-identified barriers/facilitators to retention in care and antiretroviral therapy (ART) adherence and evaluated how they mapped to ABM. Qualitative semi-structured interviews with 51 HIV-infected adults at HIV clinics in Philadelphia, PA, in 2013 were used to explore patients' experiences with HIV care and treatment. Interview data were analyzed for themes using a grounded theory approach. Among those interviewed, 53% were male and 88% were nonwhite; 49% were retained in care, 96% were on ART, and 57% were virally suppressed. Patients discussed 18 barriers/facilitators to retention in care and ART adherence: 11 common to both behaviors (stigma, mental illness, substance abuse, social support, reminder strategies, housing, insurance, symptoms, competing life activities, colocation of services, provider factors), 3 distinct to retention (transportation, clinic experiences, appointment scheduling), and 4 distinct to adherence (medication characteristics, pharmacy services, health literacy, health beliefs). Identified barriers/facilitators mapped to all ABM domains. These data support the use of ABM as a framework for classifying factors influencing HIV-specific health behaviors and have the potential to inform the design of interventions to improve retention in care and ART adherence.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/psicología , Cumplimiento de la Medicación/psicología , Aceptación de la Atención de Salud/psicología , Medicina Basada en la Evidencia , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/epidemiología , Conductas Relacionadas con la Salud , Conocimientos, Actitudes y Práctica en Salud , Humanos , Cumplimiento de la Medicación/estadística & datos numéricos , Aceptación de la Atención de Salud/estadística & datos numéricos , Philadelphia , Guías de Práctica Clínica como Asunto , Investigación Cualitativa , Estigma Social , Apoyo Social , Factores SocioeconómicosRESUMEN
BACKGROUND: Retention in HIV care improves survival and reduces the risk of HIV transmission to others. Multiple quantitative studies have described demographic and clinical characteristics associated with retention in HIV care. However, qualitative studies are needed to better understand barriers and facilitators. METHODS: Semi-structured interviews were conducted with 51 HIV-infected individuals, 25 who were retained in care and 26 not retained in care, from 3 urban clinics. Interview data were analyzed for themes using a modified grounded theory approach. Identified themes were compared between the two groups of interest: patients retained in care and those not retained in care. RESULTS: Overall, participants identified 12 barriers and 5 facilitators to retention in HIV care. On average, retained individuals provided 3 barriers, while persons not retained in care provided 5 barriers. Both groups commonly discussed depression/mental illness, feeling sick, and competing life activities as barriers. In addition, individuals not retained in care commonly reported expensive and unreliable transportation, stigma, and insufficient insurance as barriers. On average, participants in both groups referenced 2 facilitators, including the presence of social support, patient-friendly clinic services (transportation, co-location of services, scheduling/reminders), and positive relationships with providers and clinic staff. CONCLUSIONS: In our study, patients not retained in care faced more barriers, particularly social and structural barriers, than those retained in care. Developing care models where social and financial barriers are addressed, mental health and substance abuse treatment is integrated, and patient-friendly services are offered is important to keeping HIV-infected individuals engaged in care.
Asunto(s)
Infecciones por VIH/terapia , Adulto , Anciano , Instituciones de Atención Ambulatoria , Atención a la Salud , Femenino , Servicios de Salud , Humanos , Masculino , Persona de Mediana Edad , Investigación Cualitativa , Apoyo Social , Adulto JovenRESUMEN
Understanding the mechanisms of drug interactions with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) has become increasingly important because of the potential for serious adverse effects, most notably myopathy. Most of the evidence supports the role of cytochrome P450 (CYP) isoenzymes in many of these drug interactions. However, P-glycoprotein (P-gp), an efflux protein located in the gastrointestinal tract, placenta, kidneys, brain, and liver, may also play a role. Results of several studies with in vitro models have shown that lovastatin, simvastatin, and atorvastatin are inhibitors for P-gp and may be substrates for this transporter as well. Pravastatin and fluvastatin consistently demonstrate no significant inhibition of P-gp. Drug interaction studies involving statins and digoxin support a role for P-gp. Many additional drugs such as diltiazem, verapamil, itraconazole, ketoconazole, and cyclosporine, as well as dietary supplements such as St. John's wort and grapefruit juice, interact with statins and are modulators of both CYP3A4 and P-gp. However, the role of P-gp in these specific drug interactions remains unclear.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacocinética , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/antagonistas & inhibidores , Área Bajo la Curva , Interacciones Farmacológicas , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéuticoRESUMEN
Health behaviors such as retention in HIV medical care and adherence to antiretroviral therapy (ART) pose major challenges to reducing new HIV infections, addressing health disparities, and improving health outcomes. Andersen's Behavioral Model of Health Service Use provides a conceptual framework for understanding how patient and environmental factors affect health behaviors and outcomes, which can inform the design of intervention strategies. Factors affecting retention and adherence among persons with HIV include patient predisposing factors (e.g., mental illness, substance abuse), patient-enabling factors (e.g., social support, reminder strategies, medication characteristics, transportation, housing, insurance), and healthcare environment factors (e.g., pharmacy services, clinic experiences, provider characteristics). Evidence-based recommendations for improving retention and adherence include (1) systematic monitoring of clinic attendance and ART adherence; (2) use of peer or paraprofessional navigators to re-engage patients in care and help them remain in care; (3) optimization of ART regimens and pharmaceutical supply chain management systems; (4) provision of reminder devices and tools; (5) general education and counseling; (6) engagement of peer, family, and community support groups; (7) case management; and (8) targeting patients with substance abuse and mental illness. Further research is needed on effective monitoring strategies and interventions that focus on improving retention and adherence, with specific attention to the healthcare environment.
Asunto(s)
Fármacos Anti-VIH/efectos adversos , Antirretrovirales/efectos adversos , Medicina Basada en la Evidencia , Infecciones por VIH/prevención & control , Infecciones por VIH/psicología , Cumplimiento de la Medicación , Aceptación de la Atención de Salud , Fármacos Anti-VIH/uso terapéutico , Antirretrovirales/uso terapéutico , Infecciones por VIH/transmisión , Humanos , Cumplimiento de la Medicación/psicología , Modelos Psicológicos , Aceptación de la Atención de Salud/psicología , Guías de Práctica Clínica como AsuntoRESUMEN
OBJECTIVE: To determine doctor of pharmacy (PharmD) students' perceptions of a PharmD and master of public health (MPH) dual degree program. METHODS: A seven-item survey instrument was developed and distributed to students at a large metropolitan school of pharmacy during scheduled class time in April 2012. RESULTS: Among the 611 students enrolled in the PharmD program, 447 (73%) responded. Of those who responded, 72.3% were either "very likely" or "likely" to consider enrolling in such a PharmD/MPH dual degree program, and 77.4% believed that it would be attractive to future students. The most commonly identified potential limitations to pursuing the dual degree were time commitment (19.9%), increased workload and stress (11.2%), and tuition cost (10.3%). The most notable advantages documented were increased job opportunities for public health-related pharmacy positions (26.9%), increased ability to serve patients and the community (13.4%), and increased marketability for future jobs (8.7%). CONCLUSIONS: PharmD student participants demonstrated overall positive attitudes and interest towards a PharmD/MPH dual degree program.
Asunto(s)
Instituciones de Atención Ambulatoria/estadística & datos numéricos , Atención Ambulatoria/organización & administración , Actitud del Personal de Salud , Infecciones por VIH/terapia , Aceptación de la Atención de Salud/estadística & datos numéricos , Relaciones Profesional-Paciente , Adolescente , Adulto , Citas y Horarios , Femenino , Encuestas de Atención de la Salud , Humanos , Entrevistas como Asunto , Masculino , Persona de Mediana Edad , Philadelphia , Atención Primaria de Salud/organización & administración , Estigma Social , Adulto JovenRESUMEN
Objective: To determine doctor of pharmacy (PharmD) students perceptions of a PharmD and master of public health (MPH) dual degree program. Methods: A seven-item survey instrument was developed and distributed to students at a large metropolitan school of pharmacy during scheduled class time in April 2012. Results: Among the 611 students enrolled in the PharmD program, 447 (73%) responded. Of those who responded, 72.3% were either "very likely" or "likely" to consider enrolling in such a PharmD/MPH dual degree program, and 77.4% believed that it would be attractive to future students. The most commonly identified potential limitations to pursuing the dual degree were time commitment (19.9%), increased workload and stress (11.2%), and tuition cost (10.3%). The most notable advantages documented were increased job opportunities for public health-related pharmacy positions (26.9%), increased ability to serve patients and the community (13.4%), and increased marketability for future jobs (8.7%). Conclusions: PharmD student participants demonstrated overall positive attitudes and interest towards a PharmD/MPH dual degree program (AU)
Objetivo: Determinar las percepciones de los estudiantes de un programa de grado doble PharmD y Master en Salud Pública (MPH).Métodos: Se desarrolló un cuestionario de 7 preguntas y se distribuyó entre los estudiantes de una gran facultad de farmacia metropolitana durante el periodo de clases de abril 2012. Resultados: De los 611 estudiantes inscritos en el programa de PharmD, respondieron 447 (73%). De los que respondieron, el 72,3% estaban considerando "muy probablemente" o "probablemente" inscribirse en el programa de grado doble PharmD/MPH, y el 77,4% creía que sería atractivo para futuros estudiantes. Las posibles limitaciones mas frecuentemente identificadas para seguir el grado doble eran el tiempo requerido (19,9%), el incremento de trabajo y estrés (11,2%), y los costes de matrícula (10,3%). Las mayores ventajas documentadas fueron el aumento de oportunidades de trabajo en puestos de farmacia relacionados con la salud pública (26,9%), la mayor capacidad de servir a los pacientes y a la comunidad (13,4%) y la mayor facilidad de mercado para futuros puestos de trabajo (8,7%).Conclusiones: Los estudiantes de PhamD que participaron demostraron actitudes generales positivas e interés hacia un programa de grado doble PharmD/MPH (AU)